137 related articles for article (PubMed ID: 31090204)
1. Genetic variants in p53 signaling pathway genes predict chemotherapy efficacy in colorectal cancer.
Zhang K; Meng Y; Cao X; Xu Y; Du M; Wu Y; Liu L
Cancer Med; 2019 Jul; 8(7):3428-3436. PubMed ID: 31090204
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer.
Li S; Xu K; Gu D; He L; Xie L; Chen Z; Fan Z; Zhu L; Du M; Chu H; Zhang Z; Wu Y; Ni M; Wang M
J Gastroenterol; 2019 Nov; 54(11):939-949. PubMed ID: 30923916
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in RNA m
Chen S; Cao X; Ben S; Zhu L; Gu D; Wu Y; Li S; Yu Q
Cancer Med; 2023 Jan; 12(2):1376-1388. PubMed ID: 35861369
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants in Hippo signalling pathway-related genes affect the risk of colorectal cancer.
Shen H; Meng Y; Hu T; Li S; Du M; Xin J; Gu D; Wang M; Fu Z
Arch Toxicol; 2021 Jan; 95(1):271-281. PubMed ID: 33011827
[TBL] [Abstract][Full Text] [Related]
5. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
Matsusaka S; Zhang W; Cao S; Hanna DL; Sunakawa Y; Sebio A; Ueno M; Yang D; Ning Y; Parekh A; Okazaki S; Berger MD; Ichikawa W; Mizunuma N; Lenz HJ
Mol Cancer Ther; 2016 Jun; 15(6):1405-11. PubMed ID: 26983880
[TBL] [Abstract][Full Text] [Related]
6. Association of the p53 codon 72 polymorphism with clinicopathological characteristics of colorectal cancer through mRNA analysis.
De Oliveira LP; López I; Dos Santos EM; Tucci P; Marín M; Soares FA; Rossi BM; Coudry Rde A
Oncol Rep; 2014 Mar; 31(3):1396-406. PubMed ID: 24366026
[TBL] [Abstract][Full Text] [Related]
7. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Okazaki S; Schirripa M; Loupakis F; Cao S; Zhang W; Yang D; Ning Y; Berger MD; Miyamoto Y; Suenaga M; Iqubal S; Barzi A; Cremolini C; Falcone A; Battaglin F; Salvatore L; Borelli B; Helentjaris TG; Lenz HJ
Cancer; 2017 Nov; 123(22):4506-4514. PubMed ID: 28708932
[TBL] [Abstract][Full Text] [Related]
8. LUCAT1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM2-p53 pathway through binding with UBA52.
Zhou Q; Hou Z; Zuo S; Zhou X; Feng Y; Sun Y; Yuan X
Cancer Sci; 2019 Apr; 110(4):1194-1207. PubMed ID: 30690837
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Nöpel-Dünnebacke S; Schulmann K; Reinacher-Schick A; Porschen R; Schmiegel W; Tannapfel A; Graeven U
Z Gastroenterol; 2014 Dec; 52(12):1394-401. PubMed ID: 25474278
[TBL] [Abstract][Full Text] [Related]
10. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
11. EBF1-Mediated Upregulation of Ribosome Assembly Factor PNO1 Contributes to Cancer Progression by Negatively Regulating the p53 Signaling Pathway.
Shen A; Chen Y; Liu L; Huang Y; Chen H; Qi F; Lin J; Shen Z; Wu X; Wu M; Li Q; Qiu L; Yu N; Sferra TJ; Peng J
Cancer Res; 2019 May; 79(9):2257-2270. PubMed ID: 30862720
[TBL] [Abstract][Full Text] [Related]
12. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.
Chaar I; Arfaoui TA; El Amine el HO; Mahmoud LB; Khiari M; Sammoud S; Lounis A; Amara S; Gharbi L; Hmida AB; Mzabi S; Bouraoui S
Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):320-7. PubMed ID: 22266832
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants in primary cilia-related genes associated with the prognosis of first-line chemotherapy in colorectal cancer.
Qiu L; Chen S; Ben S; Cui J; Lu S; Qu R; Lv J; Shao W; Yu Q
Cancer Med; 2024 Jan; 13(2):e6996. PubMed ID: 38334481
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
[TBL] [Abstract][Full Text] [Related]
15. Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: A potential modulation of microRNAs binding.
Pardini B; Rosa F; Barone E; Di Gaetano C; Slyskova J; Novotny J; Levy M; Garritano S; Vodickova L; Buchler T; Gemignani F; Landi S; Vodicka P; Naccarati A
Clin Cancer Res; 2013 Nov; 19(21):6044-56. PubMed ID: 24036853
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract][Full Text] [Related]
17. Association study of genetic variants in estrogen metabolic pathway genes and colorectal cancer risk and survival.
Li S; Xie L; Du M; Xu K; Zhu L; Chu H; Chen J; Wang M; Zhang Z; Gu D
Arch Toxicol; 2018 Jun; 92(6):1991-1999. PubMed ID: 29766219
[TBL] [Abstract][Full Text] [Related]
18. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.
Liu L; Wu C; Wang Y; Zhong R; Duan S; Wei S; Lin S; Zhang X; Tan W; Yu D; Nie S; Miao X; Lin D
J Thorac Oncol; 2011 Nov; 6(11):1793-800. PubMed ID: 21841506
[TBL] [Abstract][Full Text] [Related]
19. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1.
Domínguez G; García JM; Peña C; Silva J; García V; Martínez L; Maximiano C; Gómez ME; Rivera JA; García-Andrade C; Bonilla F
J Clin Oncol; 2006 Feb; 24(5):805-15. PubMed ID: 16380414
[TBL] [Abstract][Full Text] [Related]
20. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
Tokunaga R; Cao S; Naseem M; Battaglin F; Lo JH; Arai H; Loupakis F; Stintzing S; Puccini A; Berger MD; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Weisenberger DJ; Liang G; Cremolini C; Heinemann V; Falcone A; Millstein J; Lenz HJ
Int J Cancer; 2019 Oct; 145(8):2082-2090. PubMed ID: 30856283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
